Lupin has disclosed under SEBI’s Regulation 30 that its wholly owned subsidiary, Lupin Pharmaceuticals Inc, has entered into a settlement agreement with Humana Inc in connection with ongoing antitrust litigation in the US.

The litigation forms part of a broader set of cases consolidated as In Re Generic Pharmaceuticals Antitrust Litigation in Philadelphia, involving allegations of anti-competitive practices and violations of federal and state antitrust laws. Lupin Pharmaceuticals Inc has denied all allegations.

The company noted that such legal proceedings are a normal part of business operations and are often resolved through settlements. In this instance, the subsidiary opted to settle to avoid prolonged litigation costs and uncertainties, particularly as other defendants in the case have already reached settlements.

Under the agreement, Lupin Pharmaceuticals Inc will pay USD 30 million in exchange for a full and final release of all claims by Humana Inc, covering the subsidiary and its related entities, directors, employees, and affiliates. The company clarified that this amount has already been accounted for in its earlier consolidated financial results.

Importantly, the settlement does not constitute any admission of liability or wrongdoing by Lupin Pharmaceuticals Inc.